Sobi Resolutions from Swedish Orphan Biovitrum´s ("Sobi") Annual General Meeting (AGM)

    Nachrichtenquelle: GlobeNewswire
     |  26.04.2012, 19:31  |  289 Aufrufe  |   | 

    The Sobi AGM convened earlier today in Stockholm and voted in favour of the
    resolutions proposed at the meeting, including:

    Adoption of the profit and loss statements and balance sheet and discharge of
    The AGM adopted the income statement and the balance sheet and approved the
    proposal to carry forward the retained profits of SEK 4,583,105,488.

    The board members and the chief executive officers were discharged from
    liability for the financial year 2011.

    Election of Board of Directors, remuneration to the Directors and election of
    The ordinary board members Adine Grate Axén, Bo Jesper Hansen, Lennart
    Johansson, Helena Saxon, Hans GCP Shikan and Hans Wigzell were re-elected and
    Matthew Gantz was elected as new board member. Bo Jesper Hansen was re-elected
    chairman of the Board.

    Matthew Gantz was born 1965 and has a BA from Princeton University and an MBA
    from Harvard Business School. He is Regional US Executive Vice President and
    General Manager US in BTG, British Technology Group. Prior to BTG, he was
    Founder and CEO of Acureon Pharmaceuticals, President and CEO of
    Hydrabiosciences Inc, VP Europe for Chiron´s Biopharmaceutical Division and
    General Manager for PathoGenesis Europe. Prior to Chiron/PathoGenesis, Matthew
    held a variety of US sales and marketing roles at Abbott Laboratories
    Diagnostics Division. Matthew Gantz does not hold any shares or options in the
    company. He is independent in relation to the company and its management and in
    relation to the company´s principal shareholders.

    The AGM approved the compensation to the Board in accordance with the nomination
    committee´s proposal.

    PricewaterhouseCoopers AB was elected auditor of Sobi until the end of the
    annual general meeting 2013.

    Nomination Committee
    The AGM approved the proposed instructions and charter for the nomination

    Principles for remuneration for the management, long-term incentive program and
    transfer of own shares
    The AGM approved the proposed guidelines for remuneration for the management.

    The AGM also approved the Board´s proposal regarding the implementation of a
    long-term incentive program, and hedging arrangements in respect of the program
    including a directed issue of no more than 1,655,136 series C shares,
    authorisation for the Board to decide on a repurchase of all issued series C
    shares and transfers of no more than 1,480,136 own common shares to program

    The Board´s proposal regarding transfer of no more than 88,551 own common shares
    on the stock exchange for the purpose of covering certain payments, mainly
    social security contributions, that may occur in relation to the Share Program
    2009, was also approved by the AGM.

    For full details on each proposal adopted by the AGM please refer to

    For more information, contact:
    Åsa Stenqvist, VP Communications and Investor Relations
    Phone: +46 8 697 20 00

    Swedish Orphan Biovitrum (Sobi)
    Sobi is a leading integrated biopharmaceutical company dedicated to bringing
    innovative therapies and services to improve the health of rare disease patients
    and their families. The product portfolio comprises about 45 marketed products
    as well as projects in the late clinical phase. Key therapeutic areas are
    Inflammation and Genetics & Metabolism. In 2011, Sobi had revenues of SEK 1.9
    billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
    Stockholm. More information is available at

    The above information has been made public in accordance with the Swedish
    Securities Market Act and/or the Financial Instruments Trading Act. The
    information was released for public distribution on April 26, 2012 at 19:30 p.m.

    Resolutions from Sobi´s AGM 2012 in pdf version:

    This announcement is distributed by Thomson Reuters on behalf of
    Thomson Reuters clients. The owner of this announcement warrants that:
    (i) the releases contained herein are protected by copyright and
    other applicable laws; and
    (ii) they are solely responsible for the content, accuracy and
    originality of the information contained therein.

    Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE

    Wertpapiere des Artikels:

    Schreibe Deinen Kommentar



    Enthaltene Werte

    WertpapierKursZeitPerf. %


    Weitere Nachrichten des Autors


    Top Nachrichten aus der Rubrik